Exkivity (mobocertinib) vs Augtyro (repotrectinib)
Exkivity (mobocertinib) vs Augtyro (repotrectinib)
Exkivity (mobocertinib) is an oral medication approved by the FDA for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has a specific mutation (EGFR Exon20 insertion mutations) and has spread to other parts of the body. Augtyro (repotrectinib), on the other hand, is a newer, investigational agent targeting ROS1 and TRK, as well as ALK-positive NSCLC, and is not yet approved as of the knowledge cutoff date. When deciding between Exkivity and Augtyro, it is important to consider the specific genetic mutations present in the cancer, the approval status of the medication, and to consult with a healthcare professional who can provide guidance based on the latest clinical evidence and individual patient circumstances.
Difference between Exkivity and Augtyro
| Metric | Exkivity (mobocertinib) | Augtyro (repotrectinib) |
|---|---|---|
| Generic name | Mobocertinib | Repotrectinib |
| Indications | Non-small cell lung cancer (NSCLC) with EGFR Exon20 insertion mutations | Advanced solid tumors with NTRK gene fusions or ROS1 rearrangements |
| Mechanism of action | EGFR tyrosine kinase inhibitor | TRK, ROS1, and ALK tyrosine kinase inhibitor |
| Brand names | Exkivity | Augtyro |
| Administrative route | Oral | Oral |
| Side effects | Diarrhea, rash, nausea, vomiting, decreased appetite | Fatigue, constipation, cough, increased blood creatinine |
| Contraindications | None known specifically, caution in patients with interstitial lung disease or QT prolongation | None known specifically, caution in patients with hepatic or renal impairment |
| Drug class | Tyrosine kinase inhibitor | Tyrosine kinase inhibitor |
| Manufacturer | Takeda Oncology | Turning Point Therapeutics, Inc. |
Efficacy
Introduction to Exkivity (Mobocertinib) in Lung Cancer Treatment
Exkivity (mobocertinib) is a medication specifically designed to target and treat non-small cell lung cancer (NSCLC) with a particular mutation known as epidermal growth factor receptor (EGFR) Exon20 insertion mutations. This targeted therapy has shown efficacy in patients who have this genetic alteration and whose disease has progressed on or after platinum-based chemotherapy. Exkivity works by inhibiting the activity of the EGFR mutation, which is a driving force in the development and progression of certain types of lung cancer.
Clinical Efficacy of Exkivity in NSCLC
The approval of mobocertinib was based on the results of a phase 1/2 clinical trial that demonstrated its efficacy in patients with EGFR Exon20 insertion-positive NSCLC. The trial reported a notable objective response rate (ORR), which is the proportion of patients with a significant reduction in tumor size. Additionally, the duration of response (DOR) was also considered encouraging, indicating that the responses to mobocertinib were not only favorable but also sustained over a period of time.
Introduction to Augtyro (Repotrectinib) in Lung Cancer Treatment
Augtyro (repotrectinib) is an investigational, next-generation tyrosine kinase inhibitor (TKI) being evaluated for the treatment of lung cancer, specifically targeting the ROS1 and NTRK fusions as well as ALK mutations. Although not yet approved, repotrectinib has shown promise in early clinical trials for treating NSCLC patients with these genetic abnormalities. Its design allows for potent inhibition of these oncogenic drivers, which are implicated in the pathogenesis of a subset of NSCLC.
Clinical Efficacy of Augtyro in NSCLC
The clinical efficacy of repotrectinib in the context of lung cancer is being assessed through ongoing clinical trials. Preliminary data suggest that repotrectinib has a high ORR in patients with advanced NSCLC harboring ROS1 fusions, including those who have been previously treated with other ROS1 inhibitors. The DOR, as well as progression-free survival (PFS), are key endpoints being evaluated to determine the potential benefit of repotrectinib in this patient population. As the clinical development of Augtyro progresses, more data will become available to further elucidate its efficacy in lung cancer treatment.
Regulatory Agency Approvals
Exkivity
-
Food and Drug Administration (FDA), USA
Augtyro
-
Food and Drug Administration (FDA), USA
Access Exkivity or Augtyro today
If Exkivity or Augtyro are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us